---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-064390"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:08:41.968475+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IO Biotech appoints David V. Smith to Board of Directors effective March 1, 2022

## Summary
- Smith appointed to Board and Audit Committee effective March 1, 2022.
- Annual director retainer $40,000; Audit Committee fee $7,500; receives 28,019 stock options vesting over 3 years.
- Smith is former EVP & CFO of Five Prime Therapeutics (acquired by Amgen) with 30+ years biotech leadership.
- No related-party transactions or arrangements regarding his selection as director.

## SEC filing metadata
- accession: 0001193125-22-064390
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/0001193125-22-064390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/d304399d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-064390
- JSON: https://secwatch.observer/filing/0001193125-22-064390.json
- Plain text: https://secwatch.observer/filing/0001193125-22-064390.txt

## Key facts
- Executive change
  David V. Smith was appointed as Director at IO Biotech, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 28, 2022, the Board of Directors of IO Biotech, Inc. (the “Company”) appointed David V. Smith as a director of the Company, effective as of March 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/0001193125-22-064390-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.